AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00403390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand Name Levothyroxine (Synthroid)
Description: Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
Study NCT00403390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic formulation of Levothyroxine
Description: Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
Study NCT03864887 — intervention group
Intervention type: PROCEDURE
Intervention: Oxygen supply of high-low-high procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
Study NCT03864887 — intervention group
Intervention type: PROCEDURE
Intervention: Oxygen supply of low-high-low procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
Study NCT03864887 — intervention group
Intervention type: DEVICE
Intervention: Optical monitor for hemodynamic parameter.
Description: Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
Study NCT04752059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
Study NCT03765983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system
Study NCT03765983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
Study NCT03228537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03228537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03228537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrapleural Pneumonectomy
Description: Undergo EPP
Study NCT03228537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT03228537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy
Description: Undergo PD
Study NCT03228537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT04333030 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Tobacco Use and Risk Questionnaire
Study NCT00794508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADA gene transfer
Description: Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
Study NCT01775449 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines
Study NCT01775449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines
Study NCT04130750 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: treatment of drug screening
Description: Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
Study NCT04130750 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: treatment of drug screening
Description: Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
Study NCT00877162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled crying and routines
Description: Behavioural (teaching and support)
Study NCT04069338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lithotripter
Description: Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
Study NCT02113618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogmed training
Description: Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
Study NCT02113618 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Training
Description: Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
Study NCT04380103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOXIRI/Bevacizumab
Description: bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
Study NCT02425605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
Study NCT02425605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
Study NCT03254927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-3379 and cetuximab
Description: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
Study NCT01584687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The patients will receive Omalizumab according to their age and weight for 4 months.
Study NCT03313752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
Study NCT03313752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00062842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01899729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 1
Description: IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
Study NCT01899729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 2
Description: IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
Study NCT01899729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 3
Description: IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
Study NCT01899729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline q wk x 12 wk by subcutaneous injection
Study NCT01899729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 4
Description: IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
Study NCT01808040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK700
Description: dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
Study NCT03706144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prodigy Math Training
Description: https://www.prodigygame.com/
Study NCT01910142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K
Description: A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
Study NCT01910142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Study NCT01910142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207 5/10mg
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10mg
Study NCT02168179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dermatologic complications management/prevention
Description: Apply KeraStat Skin Therapy topically
Study NCT02311621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
Description: Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
Study NCT02311621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)
Description: Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
Study NCT02311621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
Description: Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207 10/10mg
Study NCT01360463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Drug and Risk Counseling (BDRC)
Description: The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session.
Study NCT01360463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: methadone maintenance treatment
Description: daily individualized doses of methadone will be provided by the program staff.
Study NCT01987310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 20 mg per day for 6 months
Study NCT01987310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle counseling
Description: lifestyle modification by dietician counseling and follow up
Study NCT03988686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy plus standard care
Description: To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
Study NCT03988686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for metastatic prostate cancer
Description: androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
Study NCT03988686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care for metastatic prostate cancer
Description: androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
Study NCT02794870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 1030s vaccine
Description: 10\^5.0 PFU; administered as nose drops
Study NCT02794870 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic diluent, administered as nose drops
Study NCT03062046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF ablation
Description: RF ablation
Study NCT00782405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: XR, 150-300mg
Study NCT00782405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: 30-45 mg
Study NCT01888510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo conventional free breathing CT
Study NCT01888510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-dimensional computed tomography
Description: Undergo 4D CT
Study NCT01888510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo ABC CT
Study NCT01888510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: Undergo ABC CBCT
Study NCT01888510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: Undergo free breathing CBCT
Study NCT04194294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
Study NCT04194294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Na CL 0.9%
Description: Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
Study NCT00555841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALC and Placebo
Description: ALC and Placebo
Study NCT02168179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00555841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALC and Placebo
Description: ALC and Placebo
Study NCT04590040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0% nano-HAP toothpaste
Study NCT04590040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 15% nano-HAP toothpaste
Description: Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
Study NCT04590040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 toothpaste
Description: Toothpaste with identical base formulation as the placebo containing 5% KNO3
Study NCT02965586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal
Description: intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
Study NCT02965586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal
Description: intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
Study NCT01577589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg ceftaroline fosamil in 50 ml infusion volume
Description: IV infusion
Study NCT01577589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 50 ml infusion volume
Description: IV infusion
Study NCT01577589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 ceftaroline fosamil in 250 ml infusion volume
Description: IV infusion
Study NCT01577589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 250 ml infusion volume
Description: IV infusion
Study NCT01577589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg ceftaroline in 100 ml infusion volume
Description: IV infusion
Study NCT01577589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 100 ml infusion volume
Description: IV infusion
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Study NCT01540994 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Stereotactic Body Radiation Therapy
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207 20/10mg
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
Study NCT03803982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Blockade
Description: The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
Study NCT03803982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
Study NCT03494101 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points
Study NCT03494101 — intervention group
Intervention type: OTHER
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points
Study NCT03494101 — intervention group
Intervention type: OTHER
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires
Study NCT03328975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
Study NCT03328975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
Study NCT02988635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
Study NCT01761760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videogame-based smoking cessation intervention
Description: Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
Study NCT01761760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videogame-based smoking cessation intervention
Description: Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
Study NCT02021513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil (2.25gm EPA and 2.25gm DHA total)
Study NCT02021513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Placebo group
Study NCT02882308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 50/25 mg BD split x 5 days
Study NCT02882308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m\^2 d1-d5
Study NCT02882308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BD x 21-28 days.
Study NCT02882308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg d1